Medical/Pharmaceuticals

Global First Engineered Exosome with INCI Name -- ImmVira Leads a New Era in International Cosmetic Ingredients

SUZHOU, China, April 10, 2025 /PRNewswire/ -- EonveLab, a subsidiary of ImmVira Group ("ImmVira," or the "Company"), recently announced that its in-house developed engineered exosome product, MVR-EX103, developed for treating superficial skin depressions, has successfully passed the review of th...

2025-04-11 13:19 3038

Florida Theranostics Brings Cutting-Edge United Imaging Digital PET/CT to Palm Beach County, Florida

The uMI Panorama™ from United Imaging is the first in Florida. HOUSTON, April 10, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technology, will feature its uMI Panorama at a state-of-the-art new facility inJupiter, FL. Focused on patient-centered and preci...

2025-04-11 00:27 2289

Longevity and precision medicine driving the agenda at Abu Dhabi Global Health Week

* Global initiative addressing personalised and preventative health to be launched during the event ABU DHABI, UAE, April 10, 2025 /PRNewswire/ -- With rising global demand for more personalised and effective healthcare solutions, the Department of Health -Abu Dhabi (DoH) , the regulator of the...

2025-04-10 21:37 3529

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa ...

2025-04-10 20:00 2526

Fangzhou Showcases AI Governance Breakthroughs at Guangzhou Closed-Door Summit on Vertical-Specific AI Models

GUANGZHOU, China, April 9, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leading Internet healthcare solution provider, emerged as the sole digital health innovator invited to the Modern Industrial System Development Summit hosted by the Guangzhou Industrial Devel...

2025-04-10 11:07 4312

Harbour BioMed Appoints Youchen Chen as Chief Financial Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , April 9, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of...

2025-04-10 10:00 4445

Ractigen's RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances

* Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant target engagement, and encouraging clinical & biomarker signals * Abstract honored with prestigious "Abstracts of Distinction" award by AAN Science Committee, recogni...

2025-04-09 20:00 2680

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

SEOUL, South Korea, April 9, 2025 /PRNewswire/ -- Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in...

2025-04-09 19:54 2659

GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine

YONGIN, South Korea, April 9, 2025 /PRNewswire/ -- GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA). With the ap...

2025-04-09 12:00 2319

VARON Expands Access to Oxygen Therapy--Breathing Easier, Living Stronger

NEW YORK, April 8, 2025 /PRNewswire/ -- VARON, a leading provider of respiratory solutions, is expanding access to high-quality home oxygen concentrators, helping individuals with respiratory conditions maintain independence and an active lifestyle. For many, respirator...

2025-04-09 08:18 1966

Medit Reaffirms Commitment to American Dental Providers: No Price Increases for U.S. Customers

SEOUL, South Korea and NEWPORT BEACH, Calif., April 8, 2025 /PRNewswire/ -- Medit, a global leader in digital dentistry solutions and intraoral scanning technology, announced today that it will not raise suggested retail prices for its U.S. customers—reaffirming its commitment to accessibility, t...

2025-04-09 00:00 2642

MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025

SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clin...

2025-04-08 15:38 2689

Duality Bio Appoints Hua Mu as Global Chief Medical Officer

SHANGHAI, April 7, 2025 /PRNewswire/ -- DualityBio announced today that Dr. Hua Mu has joined the company as Global Chief Medical Officer (CMO). In this role, Dr. Mu will oversee the strategic planning, meticulous design, efficient execution, and comprehensive regulatory compliance of the company...

2025-04-07 12:52 2415

Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with schizophrenia and as a monotherapy or adjunct therapy fo...

2025-04-07 08:00 2357

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journalNature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody stapokibart, for th...

2025-04-06 10:12 3316

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

HAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effectiveTuesday, April 15, 2025, with trading to begin on a split-adjusted basi...

2025-04-05 04:05 6030

Ex-FDA Expert Dr. Yaning Wang Joins Tsingke to Drive Small Nucleic Acid Drug Innovation

BEIJING, April 4, 2025 /PRNewswire/ -- Recently, Beijing Tsingke Biotech Co., Ltd. officially announced the appointment of Dr.Yaning Wang, a former senior expert at the FDA, as the company's Chief Scientific Advisor in the field of small nucleic ac...

2025-04-04 20:58 4408

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund ("Innovation Fund")...

2025-04-03 19:30 6266

Fangzhou Designated as a 2024 National High-Tech Enterprise Amid Record Growth

BEIJING, April 3, 2025 /PRNewswire/ -- Beijing Fangyixing Information Technology Co., Ltd. ("Fangyixing"), a subsidiary ofChina's leading Internet healthcare solutions provider Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), has been certified as a 2024 National High-Tech Enterprise, sol...

2025-04-03 15:25 4059

Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II clinical trial in combination with a PD-1 Inhibitor, with...

2025-04-02 22:00 3083
1 ... 37383940414243 ... 248

Week's Top Stories